Posts

AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease

on

AZ stays on track for $80B revenue goal as cancer meds, rare disease sales help offset Ultomiris miss

on

AstraZeneca’s pipeline struggles continue with disappointing late-stage cancer and rare disease data

on

AZ wins EU nod for camizestrant

on

AstraZeneca licenses EGFR lung cancer drug Zegfrovy from spinoff Dizal for up to $1.5B

on

AZ, Ionis Shares Tumble on ATTR‑CM Trial Flop, But Analyst Flags Over‑Reaction Explained

on

AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical - Recent News

on

AstraZeneca pays Sino $200M upfront, up to $1.9B for COPD challenger to Merck’s Ohtuvayre

on

AstraZeneca seals near $1.8B renal disease pact with CSPC

on

Enhertu Approved in the EU as First Tumor Agnostic HER2-Directed Therapy for Previously Treated HER2-Positive Metastatic Solid Tumors

on

Who pays the best (and worst) in biopharma? A look at typical employee salaries

on

ADA: AZ’s oral GLP‑1 shows competitive efficacy in phase 2, setting stage for pivotal program

on

AstraZeneca CEO says AI is reshaping drug development and helping boost the odds of success

on

ASCO26: AstraZeneca unveils data it hopes will persuade FDA to approve oral SERD

on

AstraZeneca's triplet combo (Imfinzi/Imjudo/lenvatinib) plus TACE helps a subset of liver cancer patients avoid progression

on

AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi

on

FDA delays camizestrant breast cancer drug decision after ODAC vote against benefit-risk profile

on

FDA Grants Daiichi Sankyo and AstraZeneca’s Datroway a Key Breast Cancer Approval

on

AstraZeneca Wins EU Backing for Breast Cancer Drug, Splitting With FDA Panel

on

AstraZeneca wins FDA nod for first‑in‑class blood pressure pill Baxfendy

on